STOCK TITAN

Lakewood-Amedex (LABT) director lists stock and warrant holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Lakewood-Amedex Biotherapeutics Inc. director Leonard James DeRoma filed an initial Form 3 showing his existing stake in the company. He reports direct ownership of 187,736 shares of common stock.

DeRoma also holds several series of warrants to acquire common stock at exercise prices ranging from $2.13 to $5.92 per share, with expiration dates between 2028 and 2032. The filing reflects current holdings rather than new purchases or sales.

Positive

  • None.

Negative

  • None.
Insider DeRoma Leonard James
Role null
Type Security Shares Price Value
holding Warrants -- -- --
holding Warrants -- -- --
holding Warrants -- -- --
holding Warrants -- -- --
holding Warrants -- -- --
holding Warrants -- -- --
holding Common Stock; $0.0001 par value -- -- --
Holdings After Transaction: Warrants — 40,541 shares (Direct, null); Common Stock; $0.0001 par value — 187,736 shares (Direct, null)
Footnotes (1)
Common stock holdings 187,736 shares Direct ownership reported on Form 3
Warrant exercise price $2.13 per share Warrants on common stock expiring July 11 2032
Underlying shares at $2.13 8,446 shares Underlying common stock for $2.13 warrants
Warrant exercise price $2.78 per share Warrants on common stock expiring July 11 2031
Underlying shares at $2.78 8,446 shares Underlying common stock for $2.78 warrants
Warrant exercise price $2.37 per share Warrants on common stock expiring July 11 2030
Underlying shares at $2.37 8,446 shares Underlying common stock for $2.37 warrants
Largest warrant block at $5.92 40,541 shares Underlying common stock for $5.92 warrants expiring Feb 29 2028
Form 3 regulatory
"DeRoma filed an initial Form 3 showing his existing stake in the company."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
warrants financial
"DeRoma also holds several series of warrants to acquire common stock."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise price financial
"Warrants have exercise prices ranging from $2.13 to $5.92 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"Warrant expiration dates range between 2028 and 2032."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"Each warrant series lists common stock as the underlying security."
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
DeRoma Leonard James

(Last)(First)(Middle)
8031 COOPER CREEK BLVD UNIT 103

(Street)
UNIVERSITY PARK FLORIDA 34201

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
04/17/2026
3. Issuer Name and Ticker or Trading Symbol
Lakewood-Amedex Biotherapeutics Inc. [ LABT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock; $0.0001 par value187,736D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants04/01/201602/29/2028Common Stock40,541$5.92D
Warrants04/01/201702/29/2028Common Stock13,514$5.92D
Warrants01/12/201807/11/2028Common Stock33,784$5.92D
Warrants07/12/202007/11/2030Common Stock8,446$2.37D
Warrants07/12/202107/11/2031Common Stock8,446$2.78D
Warrants07/12/202207/11/2032Common Stock8,446$2.13D
Explanation of Responses:
/s/ Leonard DeRoma05/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the LABT Form 3 filing by Leonard James DeRoma show?

The Form 3 shows Leonard James DeRoma’s existing ownership in LABT, including 187,736 common shares and multiple warrant positions. It is an initial ownership report, not a record of new stock purchases or sales.

How many Lakewood-Amedex (LABT) common shares does DeRoma report?

DeRoma reports direct ownership of 187,736 shares of Lakewood-Amedex common stock. This figure reflects his holdings as of the Form 3 date and establishes a baseline for any future insider trading disclosures.

What warrants are disclosed in Leonard James DeRoma’s LABT Form 3?

The filing lists several warrant series on LABT common stock, with exercise prices from $2.13 to $5.92 per share and expirations between 2028 and 2032. Each series covers a specific number of underlying common shares.

Does the LABT Form 3 indicate that DeRoma bought or sold shares?

The Form 3 does not indicate any new purchases or sales. It is an initial statement of beneficial ownership, summarizing DeRoma’s existing common stock and warrant positions at the time he became a reporting insider.

Why is a Form 3 important for Lakewood-Amedex (LABT) investors?

Form 3 establishes an insider’s starting ownership position in LABT when they become subject to reporting rules. It helps investors track future Form 4 and Form 5 filings against this baseline to understand changes in insider holdings over time.